NEURO
About Apertum Neuro
Repeat founders.
A new delivery problem.
Apertum is being built by the co-founders of Actipulse Neuroscience: a complementary operator-scientist team with experience moving non-invasive neurotechnology from research into clinical workflows.
Visit Actipulse Neuroscience ↗01 / Shared operating history
01
Co-founder & Chief Executive Officer
Adrien
Châtillon
A health-technology entrepreneur focused on making neurotechnology more accessible—and on turning scientific capability into scalable companies.
Adrien earned a Master in International Business from Grenoble École de Management in 2013. He is a serial entrepreneur who has founded more than three startups and lived or worked across more than eight countries.
He co-founded Actipulse Neuroscience in 2017 and led the company through Y Combinator’s Winter 2022 batch. His operating thesis is direct: build medical technology around access, affordability and practical clinical adoption.
02
Co-founder & Chief Scientific Officer · MD, PhD
Gabriel
Villafuerte
A physician-neuroscientist working across neuromodulation, neurodegeneration and the translation of brain research into usable devices and protocols.
Gabriel graduated with honors from the UNAM Faculty of Medicine and completed a doctorate in neuroscience at UNAM after research in neuroimmunology and neural plasticity. His doctoral work examined conscious olfactory perception and orbitofrontal-cortex modulation.
At Actipulse he has led scientific and clinical work on low-intensity transcranial magnetic stimulation. Peer-reviewed studies bearing his authorship include a 2021 six-month Alzheimer’s pilot and a 2025 randomized crossover study reporting transient gamma-oscillation modulation.
02 / Why this team
Operating experience
meets mechanistic depth.
Actipulse centered on therapeutic neuromodulation. Apertum applies the team’s device, clinical and regulatory experience to a different bottleneck: temporarily changing the access condition around a systemic therapeutic while keeping the therapeutic itself unchanged.
03 / Profiles & publications